Core Viewpoint - The control of Duori Pharmaceutical (301075) is set to change hands to three individuals without a medical background, raising concerns about their ability to lead the company out of its current financial difficulties, as the company has reported losses in net profit this year [1][6]. Group 1: Control Change - The controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and its action partner, Zhoushan Qingchang Enterprise Management Partnership, have signed a share transfer agreement to transfer a total of 29.6% of the company's shares to natural persons Wang Qingtai, Cui Zihao, and Cao Xiaobing at a price of 32.064 yuan per share [3]. - Wang Qingtai and Cao Xiaobing plan to further increase their stake through a partial tender offer, aiming to acquire an additional 19.44 million shares, which represents 24.3% of the total share capital [3][4]. - After the completion of this transaction, the three individuals will gain control of the company [3]. Group 2: Financial Performance - Duori Pharmaceutical has faced significant financial pressure, with a reported revenue of approximately 241 million yuan in 2024, a year-on-year decrease of 28.02%, and a net profit of approximately -62.67 million yuan, marking a shift from profit to loss [6]. - In the first half of this year, the company reported a revenue of about 107 million yuan, down 29.13% year-on-year, and a net profit of approximately -42.5 million yuan, a staggering decline of 1197.26% [6]. - The transaction includes performance commitments, with projected revenues of no less than 150 million yuan for 2025 and 2026, and a net profit of no more than -90 million yuan for 2025, with expectations of returning to profitability by 2026 [6]. Group 3: Market Reaction - Following the announcement of the change in control, Duori Pharmaceutical's stock opened up 12.28% on October 14, with an opening price of 45 yuan per share, closing at 42.06 yuan, a gain of 4.94% [6]. - The total trading volume for the day reached 306 million yuan, with a total market capitalization of 3.365 billion yuan [6].

Core Viewpoint - Duori Pharmaceutical (301075) is undergoing a change in control with new shareholders lacking a background in the pharmaceutical industry, raising concerns about their ability to improve the company's performance, which has been under pressure with reported losses in net profit this year [1][6]. Group 1: Shareholder Change - On October 13, Duori Pharmaceutical announced a share transfer agreement where the controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and its associates will transfer a total of 29.6% of shares to natural persons Wang Qingtai, Cui Zihao, and Cao Xiaobing at a price of 32.064 yuan per share [4]. - Wang Qingtai and Cao Xiaobing plan to further increase their stake through a partial tender offer for 19.44 million shares, representing 24.3% of the total share capital [4][5]. - Following the completion of the share transfer, the new shareholders will gain control of the company [4]. Group 2: Financial Performance - Duori Pharmaceutical reported a revenue of approximately 241 million yuan in 2024, a year-on-year decline of 28.02%, and a net profit of -62.67 million yuan, marking a shift from profit to loss [7]. - In the first half of this year, the company also experienced a net loss of -42.5 million yuan, a significant decline of 1197.26% year-on-year, with revenues of about 107 million yuan, down 29.13% [7]. - The company has set performance commitments for the new shareholders, including a minimum revenue of 150 million yuan for 2025 and a net profit loss not exceeding 90 million yuan [7]. Group 3: Market Reaction - Following the announcement of the change in control, Duori Pharmaceutical's stock opened up by 12.28% on October 14, with an opening price of 45 yuan per share, closing at 42.06 yuan, a gain of 4.94% [7]. - The total trading volume for the day reached 306 million yuan, with a market capitalization of 3.365 billion yuan [7]. Group 4: Expert Opinion - An expert noted that the change in control could bring new opportunities and challenges, depending on whether the new shareholders can provide additional resources and market expansion opportunities [8].

Core Viewpoint - The control rights of two pharmaceutical companies, Asia-Pacific Pharmaceutical and Duori Pharmaceutical, are set to change, indicating a rapid reshuffling in the pharmaceutical industry [1][2]. Group 1: Control Changes - Asia-Pacific Pharmaceutical's controlling shareholder will change from Ningbo Fubon Holding Group to Zhejiang Xinghao Holding Partnership, which will acquire 14.61% of the shares [2][3]. - Duori Pharmaceutical's controlling shareholder will shift from Tibet Jiakang Times Technology Development to a group led by Wang Qingtai, Cui Zihao, and Cao Xiaobing, who will collectively hold 29.60% of the shares [2][6]. - The actual control of Asia-Pacific Pharmaceutical will transition from a management team to Qiu Zhongxun, while Duori Pharmaceutical's control will shift from Deng Yong to the new group [2][6]. Group 2: Stock Performance - On the first trading day after the announcement, Asia-Pacific Pharmaceutical's stock hit the daily limit, closing at 6.24 yuan per share, with a market capitalization of approximately 4.653 billion yuan [2][3]. - Duori Pharmaceutical opened high and saw an intra-day increase of 13.40%, closing at 42.06 yuan per share, with a market capitalization of about 3.365 billion yuan [2][3]. Group 3: Financial Transactions - Asia-Pacific Pharmaceutical's share transfer agreement involves a total of 1.09 billion shares at a price of 8.26 yuan per share, totaling 900 million yuan, reflecting a premium of 45.68% over the previous closing price [3][4]. - Duori Pharmaceutical's share transfer involves 2.368 million shares at a price of 32.064 yuan per share, totaling 759 million yuan [6][7]. Group 4: Financial Performance - Asia-Pacific Pharmaceutical reported a revenue of 405 million yuan in 2024, a decrease of 3.68% year-on-year, with a continued decline in the first half of the year, showing a 31.48% drop [5][6]. - The company has recorded six consecutive years of losses in net profit attributable to shareholders, with a significant loss of 4.9 billion yuan in the first half of this year [5][6]. - Duori Pharmaceutical's revenue has also seen a decline for three consecutive years, with 2022-2024 revenues of 401 million yuan, 334 million yuan, and 241 million yuan, respectively [8].

中国经济网北京10月14日讯多瑞医药（301075）(301075.SZ)今日复牌，股价开盘报45.00元，上涨 12.28%。 多瑞医药于2025年9月26日收到公司控股股东西藏嘉康时代科技发展有限公司(以下简称"西藏嘉康")、 实际控制人邓勇的通知，其正在筹划公司控制权变更相关事宜，该事项可能导致公司控股股东、实际控 制人发生变更。公司股票自2025年9月29日上午开市起停牌。 多瑞医药昨晚披露的关于控股股东及其一致行动人协议转让股份暨控制权拟发生变更的提示性公告显 示，公司控股股东西藏嘉康及其一致行动人舟山清畅企业管理合伙企业(有限合伙)(以下简称"舟山清 畅")与受让方王庆太、崔子浩、曹晓兵于2025年10月13日签署了《股份转让协议》。西藏嘉康及其一致 行动人舟山清畅拟以协议转让方式合计向王庆太及其一致行动人崔子浩、曹晓兵转让其持有的公司无限 售流通股23,680,000股(占公司总股本的29.60%)。 其中，西藏嘉康向王庆太转让4,000,000股(占上市公司股份总数的5.00%)、向崔子浩转让6,560,000股(占 上市公司股份总数的8.20%)、向曹晓兵转让7,760,000股(占上市公司 ...

北京商报讯（记者 丁宁）10月14日，多瑞医药（301075）发布公告称，10月13日，公司控股股东西藏 嘉康时代科技发展有限公司（以下简称"西藏嘉康"）及其一致行动人舟山清畅企业管理合伙企业（有限 合伙）（以下简称"舟山清畅"）与自然人王庆太、崔子浩、曹晓兵签署了《股份转让协议》，约定由西 藏嘉康及舟山清畅向受让方合计转让上市公司29.6%的股份。同时，西藏嘉康将以所持有的上市公司 1944万股的无限售条件流通股份（占公司股份总数的24.3%）就本次要约收购有效申报预受要约，并办 理预受要约的相关手续。自协议转让股份过户完成之日至要约收购完成之日，西藏嘉康放弃前述承诺预 受要约1944万股的表决权。本次交易完成后，王庆太、崔子浩、曹晓兵将取得公司控制权。 交易行情显示，10月14日，多瑞医药高开12.28%，开盘价为45元/股。 公告显示，根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第6 号——停复牌》等相关规定，经公司向深交所申请，公司股票自10月14日上午开市起复牌。 ...

智通财经APP讯，多瑞医药(301075.SZ)发布公告，公司控股股东西藏嘉康及其一致行动人舟山清畅与受 让方王庆太、崔子浩、曹晓兵签署《股份转让协议》，拟合计转让公司无限售流通股2368万股，占公司 总股本的29.60%。本次协议转让价格为32.064元/股。同时，王庆太和曹晓兵拟通过部分要约收购方式 进一步增持公司股份，拟要约收购股份数量为1944万股，占上市公司总股本的24.30%。 本次权益变动后，王庆太、崔子浩、曹晓兵合计将拥有上市公司29.60%的股份及该等股份对应的表决 权，西藏嘉康、舟山清畅合计拥有上市公司11.98%的表决权，上市公司控股股东、实际控制人变更为 王庆太、崔子浩、曹晓兵。公司股票将于2025年10月14日上午开市起复牌。 ...

每经AI快讯，多瑞医药（SZ 301075，收盘价：40.08元）10月13日晚间发布公告称，公司控股股东西藏 嘉康时代科技发展有限公司（以下简称"西藏嘉康"）及其一致行动人舟山清畅企业管理合伙企业（有限 合伙）（以下简称"舟山清畅"）与受让方王庆太、崔子浩、曹晓兵于2025年10月13日签署了《股份转让 协议》。西藏嘉康及其一致行动人舟山清畅拟以协议转让方式合计向王庆太及其一致行动人崔子浩、曹 晓兵转让其持有的公司无限售流通股23,680,000股（占公司总股本的29.60%）。本次协议转让股份来源 为公司首次公开发行前持有的股份，协议转让价格为32.064元/股，转让价格不低于公司发行并上市时 公司股票的发行价（除权除息后）26.52元/股。同时，王庆太和曹晓兵拟通过部分要约收购的方式进一 步增持上市公司的股份，拟要约收购股份数量为19,440,000股（占上市公司总股本的24.30%）。西藏嘉 康拟将其持有上市公司股份19,440,000股申报预受要约，承诺以上预受要约均为不可撤回且在要约收购 期间不得处分。自协议转让股份过户完成之日至要约收购完成之日，西藏嘉康放弃前述承诺预受要约 19,440,000 ...

每经AI快讯，多瑞医药（SZ 301075，收盘价：40.08元）10月13日晚间发布公告称，经公司向深圳证券 交易所申请，公司股票自2025年10月14日（星期二）上午开市起复牌。 截至发稿，多瑞医药市值为32亿元。 每经头条（nbdtoutiao）——中科院博导带队，中国固态电池技术又有重大突破！ （记者 曾健辉） 2024年1至12月份，多瑞医药的营业收入构成为：医药制造业占比57.85%，其他占比42.15%。 ...

每经AI快讯，10月13日，多瑞医药（301075）(301075.SZ)公告称，公司控股股东西藏嘉康及其一致行 动人舟山清畅与受让方王庆太、崔子浩、曹晓兵签署《股份转让协议》，拟合计转让公司无限售流通股 2368万股，占公司总股本的29.60%。本次协议转让价格为32.064元/股。同时，王庆太和曹晓兵拟通过 部分要约收购方式进一步增持公司股份，拟要约收购股份数量为1944万股，占上市公司总股本的 24.30%。权益变动后，王庆太、崔子浩、曹晓兵合计将拥有公司29.60%的股份及该等股份对应的表决 权，公司控股股东、实际控制人变更为王庆太、崔子浩、曹晓兵。公司股票将于2025年10月14日上午开 市起复牌。 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-079 西藏多瑞医药股份有限公司 关于豁免公司部分董事自愿性股份限售承诺的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 公司董事邓勇先生、邓勤先生申请豁免其所间接持有公司股份作 出的自愿性股份限售承诺： "上述股份锁定期届满后，在本人担任公 司董事、监事、高级管理人员期间每年转让的公司股份不超过所直接 和间接持有公司股份总数的 25%；若本人在任期届满前离职的，则在 就任时确定的任期内和任期届满后 6 个月内，每年转让的股份不超过 本人直接和间接持有的公司股份总数的 25%；离职后半年内，不转让 本人直接和间接持有的公司股份。"即申请豁免其间接持有的公司股 份每年转让不得超过 25%的限制，且离职后半年内仍继续履行承诺的 限制。 本次豁免事项已经公司第二届董事会独立董事专门会议 2025 年 第四次会议、第二届董事会第二十三次会议及第二届监事会第二十二 次会议审议通过，尚需经公司 2025 年第一次临时股东大会审议，股 东大会是否审议通过存在不确定性，敬请广大投资者注意投资风险。 ...